[Effective cyclosporine therapy to resistant-Evans syndrome]

Review OA: closed CC0
View on OpenAlex View on PubMed
⚙ AI-generated summary by qwen3.7-flash, 2026-10-13 ⓘ

Cyclosporine A therapy effectively managed refractory thrombocytopenia in a patient with Evans syndrome, maintaining platelet counts above 100,000/microliter for over 14 months after initial failure of conventional treatments.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Evans syndrome is a rare disease defined as autoimmune hemolytic anemia plus immune thrombocytopenia. We describe a 57-year-old man with Evans syndrome whose thrombocytopenia was refractory to conventional therapy, including prednisolone, danazol, azathiopurine, cyclophosphamide, vincristine, gamma-globulin and splenectomy. The patient was then treated with three cycles of pulsed high-dose dexamethasone (40 mg/day for 4 sequential days every 4 weeks) followed by cyclosporine A therapy (300 mg/day). The platelet counts dramatically increased from 2,000/microliter to 200,000/microliter. Although thrombocytopenia appeared again with the tapering of cyclosporine A, the platelet counts recovered by re-increase of cyclosporine A, and have remained above 100,000/microliter for more than 14 months. Treatment with cyclosporine A can provide an effective therapeutic choice for refractory Evans syndrome.

My notes (saved in your browser only)

MeSH descriptors

Anemia, Hemolytic, Autoimmune Cyclosporine Purpura, Thrombocytopenic, Idiopathic Anemia, Hemolytic, Autoimmune Cyclosporine Drug Resistance Humans Male Middle Aged Purpura, Thrombocytopenic, Idiopathic Syndrome

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

openalex
last seen: 2026-05-10T11:12:59.203365+00:00
pubmed
last seen: 2026-10-08T22:00:02.201502+00:00
License: CC0 · commercial use OK